Karyopharm Expanded Access Program for Selinexor

NCT07215832 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Diffuse Large B-Cell Lymphoma (DLBCL)
Sarcoma
Neuroglioblastoma
Peripheral T-cell Lymphoma
Endometrial Cancer
Myelofibrosis
Other

Interventions

DRUG: selinexor

Sponsor

Karyopharm Therapeutics Inc

Collaborators

[object Object]